Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AgfiledCriticalHoechst Ag
Priority to NZ332524ApriorityCriticalpatent/NZ332524A/en
Priority claimed from PCT/EP1996/001793external-prioritypatent/WO1997041103A1/en
Publication of NZ332524ApublicationCriticalpatent/NZ332524A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The compounds of formula I inhibit prolyl-4-hydroxylase and therefore lead to an inhibition of collagen biosynthesis. The compounds may be used in a medicament to treat fibrotic disorders of the lung, kidney, heart, eye and skin, and to treat artherosclerosis. In formula I; R1, R2 and R3 are Hydrogen, R4 is (C1-C6)-alkyl, A is CH2, in which a Hydrogen can be replaced by a methyl group, and B is CO2G, wherein G is a branched or unbranched or cyclic (C1-C20)-alkyl, a branched or unbranched or cyclic (C2-C20)-alkenyl or alkinyl radical, a corresponding (C4-C20)-alkeninyl radical, a retinyl radical, or an optionally substituted phenylalkyl radical.
NZ332524A1996-04-301996-04-303-alkoxypyridine-2-carboxylic acid amide esters as inhibitors of collagen biosynthesis
NZ332524A
(en)